Monday - May 12, 2025
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will present at the following investor conferences:
Guggenheim 5th Annual Inflammation, Neurology & Immunology (INI) Conference
Fireside Chat Date: Tuesday, November 7, 2023
Fireside Chat Time: 3:50 PM ET
Location: New York, NY
Evercore ISI 6th Annual HealthCONx Conference
Fireside Chat Date: Thursday, November 30, 2023
Fireside Chat Time: 10:50 AM ET
Location: Miami, FL
Live webcasts of the fireside chats will be available in the investor section of the company's website at investors.invivyd.com and will be archived for approximately 30 days following the events.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit https://invivyd.com/ to learn more.
Contacts:
Scott Young
(781) 208-1747
syoung@invivyd.com
Gabriella Linville-Engler
(781) 208-0160
gengler@invivyd.com
Last Trade: | US$0.84 |
Daily Change: | 0.19 30.01 |
Daily Volume: | 4,836,475 |
Market Cap: | US$100.480M |
May 12, 2025 March 20, 2025 March 05, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load